Weekly Digest – September 2025 Weekly Digest – September 2025 15 September 2025: Raludotatug deruxtecan granted Breakthrough Therapy Designation by U.S. FDA for patients with CDH6 expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers previously treated with bevacizumab Raludotatug […]
Weekly Digest – September 2025 Weekly Digest – September 2025 16 September 2025: FDA grants Fast Track Designation to Corbus Pharmaceuticals Nectin-4 targeting ADC CRB-701 in head and neck squamous cell carcinoma Corbus Pharmaceuticals announced that the FDA granted Fast […]
Weekly Digest – September 2025 Weekly Digest – September 2025 17 September 2025: Hengrui Medicine has received its marketing authorization application for a new indication for its Ruikang trastuzumab injection and has been included in the priority review process Hengrui […]
Weekly Digest – September 2025 Weekly Digest – September 2025 16 September 2025: Adagene expands SAFEbody collaboration and license agreement with Exelixis to develop third novel masked antibody-drug conjugate Adagene announced an amendment to its 2021 collaboration and license agreement with […]
Weekly Digest – September 2025 Weekly Digest – September 2025 15 September 2025: Spera Pharma and Mycenax forge strategic alliance to streamline ADC drug substance and drug product manufacturing services Spera Pharma and Mycenax Biotech have formed a strategic alliance […]
Weekly Digest – September 2025 Weekly Digest – September 2025 15 September 2025: Biocytogen announces ADC innovator Tubulis has signed global exclusive license agreement for single antibody Biocytogen announced that Tubulis has exercised an exclusive license for the global development […]
Weekly Digest – September 2025 Weekly Digest – September 2025 11 September 2025: ENHERTU Type II variation application validated in the EU for previously treated patients with HER2 positive metastatic solid tumors The EMA has validated a Type II Variation […]
Weekly Digest – September 2025 Weekly Digest – September 2025 08 September 2025: The clinical trial approval for SIM0609 (CDH17 Antibody-Drug Conjugate) issued by the National Medical Products Administration Simcere Pharmaceutical Group announced that its CDH17-targeting ADC SIM0609 received clinical […]
Weekly Digest – September 2025 Weekly Digest – September 2025 11 September 2025: Chime Biologics and Arbele announce strategic collaboration at BIOHK 2025 signing ceremony Chime Biologics and Arbele signed a strategic collaboration agreement at BIOHK 2025 to advance innovative […]
Weekly Digest – September 2025 Weekly Digest – September 2025 09 September 2025: LigaChem Biosciences enters license agreement with GO Therapeutics LigaChem Biosciences signed a licensing agreement with U.S. based GO Therapeutics to develop and commercialize ADCs using GO’s antibody […]
